Sorrento Therapeutics (SRNE) Competitors $0.0009 0.00 (-10.00%) As of 04/17/2025 03:42 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsSustainabilityTrendsBuy This Stock SRNE vs. ENTO, SHPH, EVAX, SCNI, PRFX, SXTC, VCNX, PLRZ, AKAN, and SBFMShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Entero Therapeutics (ENTO), Shuttle Pharmaceuticals (SHPH), Evaxion Biotech A/S (EVAX), Scinai Immunotherapeutics (SCNI), PainReform (PRFX), China SXT Pharmaceuticals (SXTC), Vaccinex (VCNX), Polyrizon (PLRZ), Akanda (AKAN), and Sunshine Biopharma (SBFM). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Entero Therapeutics Shuttle Pharmaceuticals Evaxion Biotech A/S Scinai Immunotherapeutics PainReform China SXT Pharmaceuticals Vaccinex Polyrizon Akanda Sunshine Biopharma Sorrento Therapeutics (NASDAQ:SRNE) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Which has better earnings and valuation, SRNE or ENTO? Entero Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.01-$572.84MN/AN/AEntero TherapeuticsN/AN/A-$15.80MN/AN/A Does the MarketBeat Community favor SRNE or ENTO? Sorrento Therapeutics received 610 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSorrento TherapeuticsOutperform Votes61067.63% Underperform Votes29232.37% Entero TherapeuticsN/AN/A Does the media prefer SRNE or ENTO? In the previous week, Sorrento Therapeutics had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for Entero Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score. Company Overall Sentiment Sorrento Therapeutics Neutral Entero Therapeutics Neutral Which has more risk & volatility, SRNE or ENTO? Sorrento Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Do insiders and institutionals believe in SRNE or ENTO? 0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 0.5% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is SRNE or ENTO more profitable? Sorrento Therapeutics' return on equity of 0.00% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A Entero Therapeutics N/A -87.06%-12.01% SummarySorrento Therapeutics beats Entero Therapeutics on 7 of the 9 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$496,000.00$2.84B$5.30B$7.34BDividend YieldN/A1.86%5.12%4.30%P/E RatioN/A30.4821.8617.80Price / Sales0.01441.91380.5497.75Price / CashN/A168.6838.2634.64Price / BookN/A3.466.453.98Net Income-$572.84M-$72.06M$3.22B$247.81M7 Day PerformanceN/A2.54%2.85%1.80%1 Month PerformanceN/A-15.71%-8.67%-6.81%1 Year PerformanceN/A-26.11%11.46%1.31% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento TherapeuticsN/A$0.00-10.0%N/A-96.8%$496,000.00$60.32M0.00800Analyst ForecastGap DownHigh Trading VolumeENTOEntero Therapeutics0.5788 of 5 stars$0.41+4.4%N/AN/A$1.94MN/A0.009Positive NewsGap DownSHPHShuttle Pharmaceuticals0.8087 of 5 stars$0.31-16.7%N/AN/A$1.91MN/A-0.075Short Interest ↑Gap DownHigh Trading VolumeEVAXEvaxion Biotech A/S1.7688 of 5 stars$1.42+5.2%$10.00+604.2%-93.8%$1.89M$3.34M-0.9860Short Interest ↑SCNIScinai Immunotherapeutics1.1593 of 5 stars$2.00+2.0%N/A-55.9%$1.87M$452,000.00-0.0120Short Interest ↓PRFXPainReform2.6598 of 5 stars$2.07-0.5%$8.00+286.5%-42.4%$1.81MN/A-0.014Short Interest ↓Gap DownSXTCChina SXT Pharmaceuticals0.2698 of 5 stars$2.50+0.4%N/A-72.7%$1.81M$1.82M0.0090Short Interest ↑Positive NewsVCNXVaccinexN/A$0.69-1.2%N/A-84.6%$1.79M$388,000.00-0.0140Gap DownPLRZPolyrizonN/A$0.40+4.5%N/AN/A$1.68MN/A0.00N/AAKANAkandaN/A$1.16+5.4%N/A-85.4%$1.66M$2.51M0.00110News CoveragePositive NewsSBFMSunshine Biopharma2.058 of 5 stars$1.31-3.7%$15.00+1,045.0%-62.3%$1.60M$34.87M-0.013Short Interest ↑Negative News Related Companies and Tools Related Companies Entero Therapeutics Competitors Shuttle Pharmaceuticals Competitors Evaxion Biotech A/S Competitors Scinai Immunotherapeutics Competitors PainReform Competitors China SXT Pharmaceuticals Competitors Vaccinex Competitors Polyrizon Competitors Akanda Competitors Sunshine Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
